Evotec SE's revenue has grown 1.6% a year over three years, and grown 9.5% a year over five. Revenue growth, 3-year annual rate: +1.6% (Drug Manufacturers - Specialty & Generic median +12%). Revenue growth, 5-year rate: +9.5%, growth has slowed since the five-year average. Years of annual history on file: 7, FY2019 to FY2025, as filed.

EVOEvotec SE

Healthcare

$1.52-62% 1Y

$1.52

$1.3452 weeks$4.15

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−13.8 points).

1 to watch, 1 neutral, 1 without data

Revenue trend−1% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +9% a year.

Margin direction−13.8 points operating

Trailing-twelve-month operating margin, -7.1% now against 6.6% a year earlier.

All from SEC EDGAR, as of Dec 31, 2025.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is EVO growing?

Evotec SE's revenue has grown 1.6% a year over three years, and grown 9.5% a year over five.

+1.6%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +12% · growing slowly · compounded from fiscal years as filed

Revenue growth, 5-year rate: +9.5%
Revenue growth, 5-year rate · +1.6% over three · growth has slowed since the five-year average
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›